In episode 157, James and Mike discuss the latest study of H pylori eradication in patients with functional dyspepsia. We discuss what to do in patients who come in with dyspeptic symptoms and when to scope, when to test, when to treat, when to say you aren’t taking any new patients. At the end we decide, to bring in another Mike (Kolber) for a future podcast to help put the whole issue into its proper perspective.

Show notes

1) Helicobacter pylori eradication in functional dyspepsia

Arch Intern Med 2011;171:1929-36

In episode 156, Mike and James inject a large dose of therapeutics into yet another PREMIUM podcast. We discuss steroid injections for trochanteric pain and which pain medication is safer for long-term use in osteoarthritis. At the end James and Mike offer to send the listeners lidocaine to dull the pain associated with listening to their latest offerings.

Show notes

1) Corticosteroid injections for trochanteric bursitis 

Ann Fam Med 2011;9:226-34

2) Fluoroscopy bursa injection vs injection by landmark

BMJ 2009;338:b1088 doi:10.1136/bmj.b1088

3) Steroid vs shock wave vs exercise

Am J Sports Med 2009;37:1981-90

4) Are corticosteroid injections effective in the management of lateral epicondylitis (tennis elbow)?

Tools For Practice

5) Osteoathritis pain – NSAIDs or narcotics – which is safer?

Arch Intern Med 2010;170:1968-78

In episode 155 Mike and James delve into the tricky area of the evidence around using antipsychotics as either monotherapy or augmentation for depression. We discuss that while there is evidence of benefit, the effect is not dissimilar to that seen with antidepressants. 

Show notes

1) Second-generation antipsychotics for major depressive disorder and dysthymia

Cochrane Library

2) Antipsychotics for depression: An acceptable risk/benefit profile?

Tools for Practice

3) Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine

Am J Psychiatry 2006;163:185–94